Immatics Teams With MD Anderson On Novel Immuno-Oncology Targets
This article was originally published in Scrip
Germany's immatics biotechnologies GMBH is establishing a US subsidiary in Houston on the campus of MD Anderson Cancer Center, and the two will work together to produce new cancer immunotherapies derived from immatics' XPRESIDENT technology platform.
You may also be interested in...
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.
Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.
Allergan strikes a pair of deals for gastrointestinal and CNS candidates, while Amgen expands its reach in bispecific antibodies via a partnership with Immatics.